ANI Pharmaceuticals cuts 2026 guidance after early headwinds
ANI Pharmaceuticals cut 2026 guidance after early-year headwinds, while saying sales-force expansion, capital allocation, and ongoing clinical programs position the business alongside revenue/EBITDA gains from rare disease and generics led by Cortrophin Gel and ILUVIEN.